NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kala Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.00 +0.01 (+0.25 %) (As of 12/8/2019 11:12 AM ET) Add Compare Today's Range$3.89Now: $4.00▼$4.0650-Day Range$3.41MA: $3.85▼$4.1752-Week Range$3.24Now: $4.00▼$9.25Volume178,900 shsAverage Volume227,411 shsMarket Capitalization$138.16 millionP/E RatioN/ADividend YieldN/ABeta2.22 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KALA Previous Symbol CUSIPN/A CIK1479419 Webhttp://www.kalarx.com/ Phone781-996-5252Debt Debt-to-Equity Ratio1.65 Current Ratio6.25 Quick Ratio5.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book1.29Profitability EPS (Most Recent Fiscal Year)($2.48) Net Income$-66,740,000.00 Net MarginsN/A Return on Equity-132.87% Return on Assets-51.10%Miscellaneous Employees130 Outstanding Shares34,540,000Market Cap$138.16 million Next Earnings Date3/9/2020 (Estimated) OptionableOptionable Receive KALA News and Ratings via Email Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KALA Rates by TradingView Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions What is Kala Pharmaceuticals' stock symbol? Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA." How were Kala Pharmaceuticals' earnings last quarter? Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.01. The company earned $1.45 million during the quarter, compared to analyst estimates of $3.56 million. View Kala Pharmaceuticals' Earnings History. When is Kala Pharmaceuticals' next earnings date? Kala Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Kala Pharmaceuticals. What price target have analysts set for KALA? 4 equities research analysts have issued 1 year price objectives for Kala Pharmaceuticals' shares. Their forecasts range from $9.00 to $51.00. On average, they expect Kala Pharmaceuticals' stock price to reach $21.25 in the next twelve months. This suggests a possible upside of 431.3% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals. What is the consensus analysts' recommendation for Kala Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals. Has Kala Pharmaceuticals been receiving favorable news coverage? Media coverage about KALA stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View News Stories for Kala Pharmaceuticals. Are investors shorting Kala Pharmaceuticals? Kala Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,940,000 shares, an increase of 6.8% from the October 31st total of 3,690,000 shares. Based on an average trading volume of 292,500 shares, the days-to-cover ratio is currently 13.5 days. Approximately 15.2% of the shares of the company are sold short. View Kala Pharmaceuticals' Current Options Chain. Who are some of Kala Pharmaceuticals' key competitors? Some companies that are related to Kala Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Aprea Therapeutics (APRE), Intra-Cellular Therapies (ITCI), Provention Bio (PRVB), Kadmon (KDMN), Magenta Therapeutics (MGTA), Viking Therapeutics (VKTX), Prothena (PRTA), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Clovis Oncology (CLVS), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), Morphic (MORF) and Dynavax Technologies (DVAX). What other stocks do shareholders of Kala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), Paratek Pharmaceuticals (PRTK), REDHILL BIOPHAR/S (RDHL), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Dynavax Technologies (DVAX). Who are Kala Pharmaceuticals' key executives? Kala Pharmaceuticals' management team includes the folowing people: Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)Mr. Todd Bazemore, Chief Operating Officer (Age 49)Dr. Kim Brazzell, Chief Medical Officer (Age 66)Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory BoardMs. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 44) When did Kala Pharmaceuticals IPO? (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. Who are Kala Pharmaceuticals' major shareholders? Kala Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.62%), State Street Corp (0.93%), Point72 Asset Management L.P. (0.90%), Boston Partners (0.36%), Wedbush Securities Inc. (0.26%) and Barclays PLC (0.04%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Institutional Ownership Trends for Kala Pharmaceuticals. Which institutional investors are selling Kala Pharmaceuticals stock? KALA stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Kala Pharmaceuticals. Which institutional investors are buying Kala Pharmaceuticals stock? KALA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., State Street Corp, Wedbush Securities Inc. and Boston Partners. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Orbimed Advisors Llc and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for Kala Pharmaceuticals. How do I buy shares of Kala Pharmaceuticals? Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Kala Pharmaceuticals' stock price today? One share of KALA stock can currently be purchased for approximately $4.00. How big of a company is Kala Pharmaceuticals? Kala Pharmaceuticals has a market capitalization of $138.16 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe.View Additional Information About Kala Pharmaceuticals. What is Kala Pharmaceuticals' official website? The official website for Kala Pharmaceuticals is http://www.kalarx.com/. How can I contact Kala Pharmaceuticals? Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected] MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 213 (Vote Outperform)Underperform Votes: 216 (Vote Underperform)Total Votes: 429MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/8/2019 by MarketBeat.com StaffFeatured Article: What does it mean to hold a stock in street name?